NVAX Financial Facts
Basic and diluted net loss per share: -0.24Loss from operations: -63.31M
See Full Income Statement
Current portion of notes payable: 45K
Accrued expenses and other current liabilities: 26.1M
See Full Balance Sheet
Novavax, Inc. (NVAX) Earnings
|
Expand Research on NVAX
| Next EPS Date | 5/7/24 | EPS Growth Rate | +72.1% |
|---|---|---|---|
| Average EPS % Beat Rate | -43.3% | Revenue Growth Rate | +85.7% |
| Average % Move 1-Wk after EPS | -8.2% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5/7/24 | Q124 | N/A | -$0.95 | N/A | N/A | $150.45M | = | N/A | N/A | ||
| 2/28/24 | Q423 | -$1.44 | -$0.45 | -$0.99 | $291M | $321.97M | = |  | | Details | |
| 11/2/23 | Q323 | N/A | -$1.74 | N/A | N/A | $184.37M | = | N/A | N/A | ||
11/9/23  |
Q323 | N/A | -$1.83 | N/A | N/A | $184.37M | = | N/A | N/A | ||
| 8/8/23 | Q223 | $0.58 | -$1.52 | +$2.10 | $424.43M | $237.39M | = | | | Details | |
| 5/9/23 | Q123 | -$3.41 | -$3.42 | +$0.01 | $81M | $95.61M | = | | | Details | |
| 2/28/23 | Q422 | -$2.28 | -$1.19 | -$1.09 | $357M | $383.14M | = | | | Details | |
| 11/8/22 | Q322 | -$4.31 | $1.63 | -$5.94 | $178.84M | $623.9M |  |
| | Details |
